Biopharma interest in ophthalmic medications is rising, especially in Europe. An overview of Bio-Europe Spring 2022 indicates that about a third of tech/products and a fourth of companies within the conference converge on ophthalmic medication. As 2022 rolls on, it is expected that there will be an uptick in the number of European ophthalmology drugs.

 Related Article: Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations

Rising Eye Health Demands

The prevalence of eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration is expected to increase every year. Over 300 million people were suffering from moderate-severe vision loss worldwide in 2021. In Europe, the incidence rate is more severe and hit an all-time high last year, with over 50 million people affected. Additionally, the ongoing COVID-19 pandemic has resulted in growing negative impacts on ocular health. Research suggests that Europe has been affected more severely than other regions. More than one-third of patients with COVID-19 had ocular involvement and nine out of ten COVID cases have received a subsequent conjunctivitis diagnosis. Moreover, vision problems and deterioration of eye health are on the rise as the digital era continues to evolve.